| 1 |
Roelfsema, F., N. R. Biermasz, A. M. Pereira, and J. A. Romijn (2008) The role of pegvisomant in the treatment of acromegaly. Expert Opin. Biol. Ther. 8: 691-704.
DOI
ScienceOn
|
| 2 |
Barnes, T. and R. Moots (2007) Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol. Int. J. Nanomedicine 2:3-7.
DOI
ScienceOn
|
| 3 |
Lu, Y., S. E. Harding, A. Turner, B. Smith, D. S. Athwal, J. G. Grossmann, K. G. Davis, and A. J. Rowe (2008) Effect of PEGylation on the solution conformation of antibody fragments. J. Pharm. Sci. 97: 2062-2079
DOI
ScienceOn
|
| 4 |
Choy, E. H., B. Hazleman, M. Smith, K. Moss, L. Lisi, D. G. Scott, J. Patel, M. Sopwith, and D. A. Isenberg (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II doubleblinded, randomized, dose-escalating trial. Rheumatology 41: 1133-1137.
DOI
|
| 5 |
Wang, Y. S., S. Youngster, M. Grace, J. Bausch, R. Bordens, and D. F. Wyss (2002) Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv. Drug Deliv. Rev. 54:547-570.
DOI
ScienceOn
|
| 6 |
Glue, P., J. W. Fang, R. Rouzier-Panis, C. Raffanel, R. Sabo, S. K. Gupta, M. Salfi, and S. Jacobs (2000) Pegylated interferonalpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin. Pharmacol. Ther. 68: 556-567.
DOI
ScienceOn
|
| 7 |
Rajender Reddy, K., M. W. Modi, and S. Pedder (2002) Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv. Drug Deliv. Rev. 54: 571-586.
DOI
ScienceOn
|
| 8 |
Zeuzem, S., J. E. Heathcote, N. Martin, K. Nieforth, and M. Modi (2001) Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin. Investig. Drugs 10: 2201-2213.
DOI
ScienceOn
|
| 9 |
Bailon, P., A. Palleroni, C. A. Schaffer, C. L. Spence, W. J. Fung, J. E. Porter, G. K. Ehrlich, W. Pan, Z. X. Xu, M. W. Modi, A. Farid, W. Berthold, and M. Graves (2001) Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug. Chem. 12: 195-202.
DOI
ScienceOn
|
| 10 |
Monkarsh, S. P., Y. Ma, A. Aglione, P. Bailon, D. Ciolek, B. DeBarbieri, M. C. Graves, K. Hollfelder, H. Michel, A. Palleroni, J. E. Porter, E. Russoman, S. Roy, and Y. C. Pan (1997) Positional isomers of monopegylated interferon alpha-2a: isolation, characterization, and biological activity. Anal. Biochem. 247: 434-440.
DOI
ScienceOn
|
| 11 |
Molineux, G. (2003) Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anticancer Drugs 14: 259-264.
DOI
ScienceOn
|
| 12 |
Yang (2006) Pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects. J. Clin. Pharmacol. 46: 747-757.
DOI
ScienceOn
|
| 13 |
Fuh, G., B. C. Cunningham, R. Fukunaga, S. Nagata, D. V. Goeddel, and J. A. Wells (1992) Rational design of potent antagonists to the human growth hormone receptor. Science 256: 1677-1680.
DOI
|
| 14 |
Pradhananga, S., I. Wilkinson, and R. J. Ross (2002) Pegvisomant: structure and function. J. Mol. Endocrinol. 29: 11-14.
DOI
ScienceOn
|
| 15 |
Roelfsema, F., N. R. Biermasz, A. M. Pereira, and J. Romijn (2006) Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int. J. Nanomedicine 1: 385-398.
DOI
ScienceOn
|
| 16 |
Na, D. H., Y. S. Youn, and K. C. Lee (2004) Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring and optimization of site-specific PEGylation of ricin A-chain. Rapid Commun. Mass Spectrom. 18: 2185-2189.
DOI
ScienceOn
|
| 17 |
Chan, B., D. Wara, J. Bastian, M. S. Hershfield, J. Bohnsack, C. G. Azen, R. Parkman, K. Weinberg, and D. B. Kohn (2005) Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID). Clin. Immunol. 117: 133-143.
DOI
ScienceOn
|
| 18 |
Pepinsky, R. B., R. I. Shapiro, S. Wang, A. Chakraborty, A. Gill, D. J. Lepage, D. Wen, P. Rayhorn, G. S. Horan, F. R. Taylor, E. A. Garber, A. Galdes, and T. M. Engber (2002) Long-acting forms of Sonic hedgehog with improved pharmacokinetic and pharmacodynamic properties are efficacious in a nerve injury model. J. Pharm. Sci. 91: 371-387.
DOI
ScienceOn
|
| 19 |
Youn, Y. S., D. H. Na, S. D. Yoo, S. C. Song, and K. C. Lee (2005) Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential. Int. J. Biochem. Cell Biol. 37: 1525-1533.
DOI
ScienceOn
|
| 20 |
Davis, F. F. (2003) PEG-adenosine deaminase and PEGasparaginase. Adv. Exp. Med. Biol. 519: 51-68.
|
| 21 |
Davis, S., A. Abuchowski, Y. K. Park, and F. F. Davis (1981) Alteration of the circulating life and antigenic properties of bovine adenosine deaminase in mice by attachment ofpolyethylene glycol. Clin. Exp. Immunol. 46: 649-652.
|
| 22 |
Graham, M. L. (2003) Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55: 1293-1302.
DOI
ScienceOn
|
| 23 |
Kamisaki, Y., H. Wada, T. Yagura, A. Matsushima, and Y. Inada (1981) Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol. J. Pharmacol. Exp. Ther. 216: 410-414.
|
| 24 |
Ho, D. H., N. S. Brown, A. Yen, R. Holmes, M. Keating, A. Abuchowski, R. A. Newman, and I. H. Krakoff (1986) Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab. Dispos. 14: 349-352.
|
| 25 |
Wylie, D. C., M. Voloch, S. Lee, Y. H. Liu, S. Cannon-Carlson, C. Cutler, and B. Pramanik (2001) Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharm. Res. 18: 1354-1360.
DOI
ScienceOn
|
| 26 |
Wang, Y. S., S. Youngster, J. Bausch, R. Zhang, C. McNemar, and D. F. Wyss (2000) Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 39: 10634-10640.
DOI
ScienceOn
|
| 27 |
Yamaoka, T., Y. Tabata, and Y.Ikada (1994) Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83: 601-606.
DOI
ScienceOn
|
| 28 |
Herold, D. A., K. Keil, and D. E. Bruns (1989) Oxidation of polyethylene glycols by alcohol dehydrogenase. Biochem. Pharmacol. 38: 73-76.
DOI
ScienceOn
|
| 29 |
Richter, A. W. and E. Akerblom (1983) Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int. Arch. Allergy Appl. Immunol. 70: 124-131.
DOI
|
| 30 |
Richter, A. W. and E. Akerblom (1984) Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors. Int. Arch. Allergy Appl. Immunol. 74: 36-39.
DOI
|
| 31 |
Caliceti, P. and F. M. Veronese (2003) Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55: 1261-1277.
DOI
ScienceOn
|
| 32 |
Park, E. J. and D. H. Na (2008) Optimization of octreotide PEGylation by monitoring with fast reversed-phase highperformance liquid chromatography. Anal. Biochem. 380: 140-142.
DOI
ScienceOn
|
| 33 |
Lee, K. S. and D. H. Na (2010) Capillary electrophoretic separation of poly(ethylene glycol)-modified granulocyte-colony stimulating factor. Arch. Pharm. Res. 33: 491-495.
DOI
|
| 34 |
Park, E. J., K. S. Lee, K. C. Lee, and D. H. Na (2010) Application of microchip CGE for the analysis of PEG-modified recombinant human granulocyte-colony stimulating factors. Electrophoresis 31: 3771-3774.
DOI
|
| 35 |
Kinstler, O. B., D. N. Brems, S. L. Lauren, A. G. Paige, J. B. Hamburger, and M. J. Treuheit (1996) Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. 13: 996-1002.
DOI
ScienceOn
|
| 36 |
Kinstler, O., G. Molineux, M. Treuheit, D. Ladd, and C. Gegg (2002) Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 54: 477-485.
DOI
ScienceOn
|
| 37 |
Abuchowski, A., T. van Es, N. C. Palczuk, and F. F. Davis (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J. Biol. Chem. 252: 3578-3581.
|
| 38 |
Roberts, M. J., M. D. Bentley, and J. M. Harris (2002) Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. 54: 459-476.
DOI
ScienceOn
|
| 39 |
Lawrence, S. (2007) Billion dollar babies-biotech drugs as blockbusters. Nature Biotech. 25: 380-382.
DOI
ScienceOn
|
| 40 |
Abuchowski, A., J. R. McCoy, N. C. Palczuk, T. van Es, and F. F. Davis (1977) Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem. 252: 3582-3586.
|
| 41 |
Veronese, F. M. and A. Mero (2008) The impact of PEGylation on biological therapies. BioDrugs 22: 315-329.
DOI
ScienceOn
|
| 42 |
Kang, J. S., P. P. Deluca, and K. C. Lee (2009) Emerging PEGylated drugs. Expert Opin. Emerg. Drugs 14: 363-380.
DOI
ScienceOn
|
| 43 |
Gaberc-Porekar, V., I. Zore, B. Podobnik, and V. Menart (2008) Obstacles and pitfalls in the PEGylation of therapeutic proteins. Curr. Opin. Drug Discov. Devel. 11: 242-250.
|
| 44 |
Mero, A., B. Spolaore, F. M. Veronese, and A. Fontana (2009) Transglutaminase-mediated PEGylation of proteins: direct identification of the sites of protein modification by mass spectrometry using a novel monodisperse PEG. Bioconjug. Chem. 20: 384-389.
DOI
ScienceOn
|
| 45 |
Filpula, D. and H. Zhao (2008) Releasable PEGylation of proteins with customized linkers. Adv. Drug Deliv. Rev. 60: 29-49.
DOI
ScienceOn
|
webmaster
